ERBB2 and breast cancer: In contrast, a study by O’Brien et al., from the Carolina Breast Cancer Study (CBCS), evaluated breast cancer–specific survival (BCSS) in 246 Black and 379 White women with HR+/HER2-breast cancer and found that Black women were significantly more likely to die of disease than White women, even after adjusting for age, date and stage at diagnosis (HR 1.9, 95% CI 1.3–2.9) [5].